Compare BRKR & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRKR | ALKS |
|---|---|---|
| Founded | 1960 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.5B |
| IPO Year | 2000 | 2012 |
| Metric | BRKR | ALKS |
|---|---|---|
| Price | $36.14 | $35.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 14 |
| Target Price | ★ $48.92 | $43.29 |
| AVG Volume (30 Days) | 1.9M | ★ 2.0M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.43 |
| Revenue | ★ $1,895,600,000.00 | $1,475,899,000.00 |
| Revenue This Year | $6.27 | $24.26 |
| Revenue Next Year | $3.78 | $4.63 |
| P/E Ratio | ★ N/A | $21.11 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.53 | $25.17 |
| 52 Week High | $56.22 | $36.32 |
| Indicator | BRKR | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 47.69 | 74.10 |
| Support Level | $35.88 | $27.89 |
| Resistance Level | $37.64 | $35.65 |
| Average True Range (ATR) | 1.78 | 1.18 |
| MACD | 0.38 | 0.74 |
| Stochastic Oscillator | 78.96 | 91.05 |
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.